

Etifoxine

A non-benzodiazepine benzoxazine derivative developed by Hoechst AG and marketed as Stresam, distinguished from classical benzodiazepine anxiolytics by a dual mechanism encompassing direct positive allosteric modulation of beta2/beta3-containing GABAA receptors and stimulation of endogenous neurosteroid biosynthesis through the 18 kDa translocator protein (TSPO), conferring anxiolytic, anticonvulsant, and neuroprotective activity without the sedation, amnesia, tolerance, and dependence liabilities of the benzodiazepine class.

DOCUMENT

KDC-MN-1585

ISSUED

2026-05-20

REVISION

1.0

AUTHOR

Kodiac bioLabs Research

COMPOUND CLASS

Non-benzodiazepine benzoxazine anxiolytic with dual GABAA receptor positive allosteric modulation and TSPO-mediated neurosteroidogenesis

ABSTRACT

RESEARCH USE ONLY

kodiac.org

Etifoxine (6-chloro-N-ethyl-4-methyl-4-phenyl-4H-3,1-benzoxazin-2-amine) is a non-benzodiazepine anxiolytic of the benzoxazine structural class, first synthesized by Hoechst AG in 1966 and introduced for clinical use in France in 1979 under the trade name Stresam. The compound is marketed in approximately 40 countries for the treatment of anxiety disorders, principally adjustment disorders with anxiety, but has not been approved by the United States Food and Drug Administration or by the European Medicines Agency for centralized marketing authorization across the European Union. Etifoxine is pharmacologically distinguished from both the benzodiazepine class and from other non-benzodiazepine anxiolytics (buspirone, hydroxyzine) by a dual mechanism of action at the GABAergic system. The first mechanism is direct positive allosteric modulation of the GABAA receptor through binding at the beta subunit, with preferential potentiation of receptors containing beta2 or beta3 subunits, at a site distinct from the benzodiazepine binding site located at the alpha/gamma interface. The second mechanism is binding to the 18 kDa translocator protein (TSPO, formerly the peripheral benzodiazepine receptor) on the outer mitochondrial membrane, which stimulates the translocation of cholesterol into the mitochondrial matrix and the subsequent biosynthesis of endogenous neurosteroids, principally pregnenolone, progesterone, 5-alpha-dihydroprogesterone, and allopregnanolone. Allopregnanolone is itself a potent positive allosteric modulator of the GABAA receptor at the neurosteroid binding site (distinct from both the benzodiazepine and the etifoxine direct binding sites), producing a convergent, temporally

extended potentiation of GABAergic inhibitory neurotransmission. This dual mechanism produces anxiolytic efficacy comparable to benzodiazepines in clinical trials of adjustment disorder with anxiety, with significantly reduced incidence of sedation, psychomotor impairment, amnesia, rebound anxiety on withdrawal, and physical dependence. Pharmacokinetics are characterized by rapid oral absorption, high bioavailability (approximately 90 percent), hepatic metabolism to an active metabolite (diethyl-etifoxine) with a half-life of approximately 20 hours, and predominant renal excretion. The clinical evidence base includes multiple randomized controlled trials comparing etifoxine to lorazepam, alprazolam, and placebo in adjustment disorder with anxiety, with the AMETIS study (a three-arm trial versus lorazepam and placebo) producing a notable negative result in which neither active arm separated from placebo. The compound has an established clinical safety profile over more than 40 years of marketed use, with rare but serious adverse events including severe cutaneous reactions (drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome, erythema multiforme) and hepatotoxicity (acute cytolytic hepatitis), which prompted a 2021 European Medicines Agency Article 31 referral concluded in January 2022 with continued marketing authorization subject to contraindication in patients with prior severe dermatological or hepatic reactions. Beyond the anxiolytic indication, etifoxine has generated a substantial preclinical research literature in neuroprotection following peripheral nerve injury, traumatic brain injury, experimental autoimmune encephalomyelitis (a model of multiple sclerosis), and neuropathic pain, with the neuroprotective activity attributed to TSPO-mediated neurosteroidogenesis and downstream anti-inflammatory and

neurotrophic effects. A deuterated analog, GRX-917 (GABA Therapeutics, a subsidiary of atai Life Sciences), has completed Phase 1 clinical trials with improved pharmacokinetic properties and is in development for anxiety and related disorders. This monograph reviews the chemistry, synthesis, and structural classification of etifoxine; the dual-receptor mechanism in molecular and electrophysiological detail; the comprehensive pharmacokinetic record; the preclinical pharmacology across neuroprotection, nerve injury, traumatic brain injury, and pain models; the clinical evidence base in anxiety disorders; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event signal including the EMA referral outcome; and a comparative assessment of five anxiolytic alternatives against etifoxine on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

International Nonproprietary Name: Etifoxine.

Marketed names: Stresam (Biocodex; France, Russia, several Eastern European and Asian jurisdictions). The trade name Stresam is the canonical commercial identifier for etifoxine in all marketed jurisdictions. Generic forms are available in some markets under the name etifoxine hydrochloride.

Development codes: HOE 36801 (Hoechst AG). The Hoechst code is the original development identifier under which early pharmacological characterization and synthesis reports were published.

Chemical Abstracts Service registry numbers: 21715-46-8 (free base), 56776-32-0 (hydrochloride salt). The hydrochloride salt is the pharmaceutical form used in all marketed oral formulations.

International Union of Pure and Applied Chemistry name: 6-chloro-N-ethyl-4-methyl-4-phenyl-4H-3,1-benzoxazin-2-amine. The compound is a 1,3-benzoxazine derivative bearing a chlorine substituent at position 6, a methyl group and a phenyl group at position 4, and an ethylamino group at position 2.

1.2 Structural class and chemistry

Etifoxine is a 2-amino-4H-3,1-benzoxazine derivative, placing it within the broader benzoxazine heterocyclic class. The benzoxazine ring system consists of a benzene ring fused to a six-membered 1,3-oxazine ring containing one oxygen and one nitrogen atom. This structural class is distinct from the benzodiazepine ring system (a benzene ring fused to a seven-membered 1,4-diazepine ring) and from the cyclopyrrolone, imidazopyridine, and pyrazolopyrimidine scaffolds of other non-benzodiazepine hypnotics and anxiolytics [1].

Molecular formula: C₁₇H₁₇ClN₂O (free base); C₁₇H₁₈Cl₂N₂O (hydrochloride salt).

Molecular weight: 300.78 g/mol (free base); 337.24 g/mol (hydrochloride salt).

Physical properties: White to off-white crystalline powder. Soluble in methanol and ethanol; sparingly soluble in water as the free base; the hydrochloride salt has improved aqueous solubility. Melting point of the hydrochloride salt is approximately 191 to 194 degrees Celsius.

Stereochemistry: Etifoxine contains one stereocenter at carbon 4 of the benzoxazine ring, which bears both the methyl and phenyl substituents. The marketed material is the racemate. The (S)-enantiomer has been studied as a separate entity in some pharmacological investigations, but no enantioselective advantage has been established that would warrant chiral separation for clinical use.

1.3 Synthesis

The synthesis of etifoxine proceeds through construction of the 3,1-benzoxazine ring system. The general synthetic route involves condensation of 2-amino-4-chlorophenol with acetophenone under acid-catalyzed conditions to form the 4-methyl-4-phenyl-4H-3,1-benzoxazine intermediate, followed by introduction of the 2-ethylamino substituent through reaction with ethyl isocyanate or through a two-step sequence involving formation of the 2-chloro intermediate and subsequent displacement with ethylamine [2]. The product is purified by recrystallization from appropriate solvent systems (typically ethanol or isopropanol) and converted to the hydrochloride salt by treatment with hydrogen chloride in an organic solvent. The hydrochloride is recrystallized and characterized by nuclear magnetic resonance spectroscopy, melting point determination, and high-performance liquid chromatography. Industrial synthesis achieves yields in the range of 60 to 80 percent for the ring-closure step. A radiolabeled synthesis of [4-¹⁴C]-etifoxine has been reported for metabolic and pharmacokinetic studies [2].

2. Abstract

Etifoxine (HOE 36801, Stresam) is a non-benzodiazepine anxiolytic of the benzoxazine structural class that produces GABAergic potentiation through two convergent but mechanistically independent pathways: direct positive allosteric modulation of the GABAA receptor at a beta-subunit binding site, and stimulation of endogenous neurosteroid biosynthesis through binding to the mitochondrial 18 kDa translocator protein (TSPO) [3, 4]. The dual mechanism distinguishes etifoxine from benzodiazepines (which act exclusively at the alpha/gamma interface of the GABAA receptor), from buspirone (a 5-HT1A partial agonist with no direct GABAergic activity), and from hydroxyzine (an H1 antihistamine with secondary anticholinergic and anxiolytic properties).

The compound was synthesized by Hoechst AG in 1966 and introduced for clinical use in France in 1979. It is currently marketed in approximately 40 countries under the trade name Stresam for the treatment of adjustment disorders with anxiety, at an oral dose of 150 to 200 mg per day in divided doses (50 mg three times daily or 100 mg twice daily). The compound is not approved by the United States Food and Drug Administration, and a 2021 European Medicines Agency Article 31 referral concluded with continued marketing authorization subject to new contraindications and risk-minimization measures [5].

Clinical efficacy in adjustment disorder with anxiety has been demonstrated in randomized controlled trials comparing etifoxine to lorazepam and to alprazolam, with non-inferior anxiolytic efficacy (Hamilton Anxiety Rating Scale score reduction of approximately 55 percent versus 52 percent for lorazepam) and a significantly lower rate of rebound anxiety on treatment discontinuation [6, 7]. The AMETIS study, a three-arm randomized controlled trial comparing etifoxine, lorazepam, and placebo, produced a negative result in which neither active treatment separated statistically from placebo, raising questions about assay sensitivity in the adjustment disorder indication [5, 8].

The preclinical pharmacology of etifoxine extends substantially beyond the anxiolytic indication. The TSPO-mediated neurosteroidogenic activity produces neuroprotective effects in animal models of peripheral nerve injury (sciatic nerve crush and cryolesion), traumatic brain injury, and experimental autoimmune en-

cephalomyelitis, with mechanisms including enhanced axonal regeneration, reduced neuroinflammation, increased expression of neurotrophic factors (nerve growth factor, glial cell-derived neurotrophic factor, vascular endothelial growth factor), and restored mitochondrial oxidative phosphorylation [9, 10, 11, 12]. These neuroprotective applications have not been translated to human clinical trials as of the current monograph revision.

A deuterated analog, GRX-917, developed by GABA Therapeutics (a subsidiary of Atai Life Sciences), completed Phase 1 single and multiple ascending dose trials in 2023 with favorable safety, tolerability, and improved pharmacokinetic properties (longer half-life, anticipated once-daily dosing), and demonstrated target engagement via quantitative electroencephalography frontal beta power [13]. GRX-917 represents a next-generation development strategy for the etifoxine mechanism.

3. Discovery and Development History

3.1 Origin

Etifoxine was first synthesized in 1966 at Hoechst AG (Frankfurt am Main, Germany) as part of a medicinal chemistry program exploring benzoxazine heterocycles as potential central nervous system agents. The program was motivated by the desire to develop anxiolytic compounds that would avoid the sedation, psychomotor impairment, and dependence liabilities that were already recognized as limitations of the benzodiazepine class, which had been introduced commercially with chlordiazepoxide (Librium, 1960) and diazepam (Valium, 1963) [1].

3.2 Early pharmacological characterization

Studies published in 1972 established the pharmacological profile of etifoxine, demonstrating anxiolytic, anticonvulsant, and muscle-relaxant (spasmolytic) activity in standard rodent behavioral and electrophysiological models. The anxiolytic activity was observed at doses that did not produce sedation or ataxia, a separation from benzodiazepines that was recognized as the principal differentiating feature [14]. The anticonvulsant activity was demonstrated against pentylenetetrazol-induced seizures, consistent with GABAergic enhancement.

3.3 Clinical introduction

Etifoxine received marketing authorization in France in 1979 under the trade name Stresam, with the indication for psychosomatic manifestations of anxiety. The marketing authorization holder was Biocodex (Gentilly, France), which has remained the principal sponsor throughout the commercial life of the compound. The compound was subsequently registered in approximately 40 additional countries, predominantly in Eastern Europe, Russia, North Africa, the Middle East, and selected Asian markets [1].

3.4 Mechanistic elucidation

The mechanism of action of etifoxine was incompletely understood at the time of initial marketing authorization. The GABAA receptor interaction was characterized in the 1990s and early 2000s through electrophysiological studies in heterologous expression systems. Hamon et al. (2003) demonstrated that the modulatory effects of etifoxine on GABAA receptors are mediated by the beta subunit, with preferential potentiation at beta2- and beta3-containing receptors, at a binding site distinct from the benzodiazepine site [15]. Schlichter et al. (2000) characterized the direct chloride current evoked by etifoxine in oocytes expressing alpha-beta receptor combinations and demonstrated beta-subunit dependence of the potentiation [16].

The TSPO-mediated neurosteroidogenic mechanism was characterized by Verleye et al. (2005), who demonstrated that intraperitoneal administration of etifoxine increased plasma and brain concentrations of pregnenolone, progesterone, 5-alpha-dihydroprogesterone, and allopregnanolone, and that selective inhibitors of neurosteroidogenesis (finasteride, aminoglutethimide) partially abolished the anxiolytic effect of etifoxine in rodent behavioral models [17]. Wolf et al. (2015) subsequently demonstrated that etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis, further elucidating the temporal dynamics of the neurosteroidogenic pathway [18].

3.5 Regulatory review

The European Medicines Agency initiated an Article 31 referral for etifoxine-containing medicinal products in June 2021, at the request of the French National Agency for Medicines and Health Products Safety (ANSM), to assess the benefit-risk balance following the negative AMETIS study results and cumulative pharmacovigilance data on severe cutaneous and hepatic adverse reactions. The Committee for Medicinal Products for Human Use (CHMP) concluded on 27 January 2022 that etifoxine can continue to be used for the treatment of anxiety disorders, subject to new contraindications (prior severe skin reactions or severe hepatic reactions to etifoxine), updated product information, and enhanced risk-minimization measures [5].

3.6 Deuterated analog development

GABA Therapeutics, a subsidiary of atai Life Sciences, initiated development of GRX-917, a deuterated form of etifoxine designed to improve the pharmacokinetic profile through the deuterium kinetic isotope effect, which slows cytochrome P450-mediated metabolism and extends the elimination half-life. GABA Therapeutics completed a Phase 1 single and multiple ascending dose study in Australia in 2023, reporting favorable safety, tolerability, and pharmacokinetic properties consistent with once-daily dosing [13].

4. Mechanism of Action

Etifoxine produces anxiolytic, anticonvulsant, and neuroprotective activity through two complementary but mechanistically independent pathways that converge on potentiation of GABAergic inhibitory neurotransmission. A third, less well characterized activity is emerging in the neuroprotection literature through TSPO-mediated mitochondrial function.

4.1 Direct GABAA receptor positive allosteric modulation

The GABAA receptor is a heteropentameric ligand-gated chloride channel of the Cys-loop superfamily, typically composed of two alpha, two beta, and one gamma subunit in the predominant synaptic configuration (alpha1-beta2-gamma2 being the most abundant subtype in the mammalian brain). Multiple pharmacologically distinct allosteric binding sites exist on the receptor: the benzodiazepine site (at the alpha/gamma subunit interface), the barbiturate site, the neurosteroid site (at the transmembrane domain), and additional modulatory sites at the beta subunit interface.

Etifoxine binds at the beta subunit of the GABAA receptor. Hamon et al. (2003) demonstrated in *Xenopus* oocytes expressing defined GABAA receptor subunit combinations that etifoxine evokes chloride current in the absence of GABA at alpha1-beta(x) receptors (where x = 1, 2, or 3) and potentiates GABA-activated currents in a dose-dependent manner [15]. The potentiation is beta-subunit-dependent: receptors containing beta2 or beta3 subunits are potentiated to a significantly greater extent than receptors containing beta1 subunits. This subunit selectivity distinguishes etifoxine from benzodiazepines (which require the gamma subunit and act at the alpha/gamma interface) and from barbiturates (which act at a distinct transmembrane site).

Bhatt et al. (2019) further characterized the involvement of the alpha subunit in etifoxine modulation, demonstrating through molecular modeling that etifoxine interacts with a pocket at the alpha/beta subunit interface homologous to the GABA binding site, suggesting an allosteric mechanism that facilitates channel opening through conformational coupling to the orthosteric site [19].

The functional consequence of the direct GABAA modulation is enhancement of chloride conductance, membrane hyperpolarization, and reduction of neuronal excitability. At therapeutic concentrations (low micromolar), etifoxine produces anxiolytic effects through potentiation of GABAergic transmission in limbic circuits (amygdala, prefrontal cortex, hippocampus) without the global cortical depression that produces the sedative and amnestic effects of benzodiazepines.

4.2 TSPO-mediated neurosteroid biosynthesis

The 18 kDa translocator protein (TSPO, formerly known as the peripheral benzodiazepine receptor) is an integral membrane protein located on the outer mitochondrial membrane. Its principal physiological function is the translocation of cholesterol from the outer to the inner mitochondrial membrane, the rate-limiting step in steroidogenesis. In steroidogenic tissues (adrenal cortex, gonads) and in the central nervous system (astrocytes, microglia, and neurons), cholesterol translocation initiates the biosynthetic cascade from cholesterol through pregnenolone, progesterone, and the 5-alpha-reduced neurosteroids (5-alpha-dihydroprogesterone and allopregnanolone) [3, 4].

Etifoxine binds to TSPO and stimulates cholesterol translocation, increasing the rate of neurosteroid biosynthesis. Verleye et al. (2005) demonstrated that systemic etifoxine administration in rodents produces dose-dependent increases in plasma and brain concentrations of pregnenolone (approximately 2-fold increase), progesterone (approximately 1.5-fold), 5-alpha-dihydroprogesterone, and allopregnanolone [17]. The allopregnanolone increase is the pharmacologically most consequential product, as allopregnanolone is a potent positive allosteric modulator of the GABAA receptor at the neurosteroid binding site (located in the transmembrane domain, distinct from both the benzodiazepine site and the etifoxine direct binding site). The effective concentration of allopregnanolone for GABAA receptor potentiation is in the low nanomolar range, and the etifoxine-induced elevation is sufficient to produce functionally meaningful receptor potentiation [20].

The neurosteroidogenic mechanism produces a temporally extended anxiolytic effect that persists beyond the direct GABAA receptor modulation. The half-life of allopregnanolone in brain tissue is longer than the plasma half-life of etifoxine itself, providing a pharmacodynamic buffer. The dual mechanism (direct receptor

modulation plus neurosteroid synthesis) produces a composite anxiolytic signal with both rapid-onset (direct modulation) and sustained (neurosteroid-mediated) components.

Verleye et al. (2005) demonstrated that the selective neurosteroidogenesis inhibitors finasteride (5-alpha-reductase inhibitor) and aminoglutethimide (cytochrome P450 side-chain cleavage inhibitor) partially but not completely abolished the anxiolytic effect of etifoxine in the elevated plus maze, confirming that both the direct and indirect pathways contribute to the anxiolytic activity [17].

4.3 Anti-inflammatory and neuroprotective pathways

TSPO activation by etifoxine has consequences beyond neurosteroid synthesis. TSPO is expressed at elevated density in activated microglia and reactive astrocytes in the central nervous system, and in peripheral macrophages and immune cells. Activation of TSPO in these cell types modulates mitochondrial function, reduces oxidative stress, and attenuates pro-inflammatory cytokine release (tumor necrosis factor-alpha, interleukin-1-beta, interleukin-6) [9, 10]. These anti-inflammatory effects are mediated both through the neurosteroid products (progesterone and allopregnanolone have direct anti-inflammatory activity) and through TSPO-dependent regulation of mitochondrial permeability transition pore opening and reactive oxygen species production.

Simon-O'Brien et al. (2016) demonstrated that etifoxine reduces glial activation, neuronal degeneration, and neuroinflammation in a rat model of traumatic brain injury, with effects including reduced lesion volume, enhanced neuron survival, and decreased apoptotic activity [10]. Ma et al. (2021) further showed that etifoxine restores mitochondrial oxidative phosphorylation and improves cognitive recovery following traumatic brain injury, indicating a direct mitochondrial mechanism beyond the neurosteroid pathway [12].

4.4 Composite pharmacology

The composite pharmacology of etifoxine at the recommended oral dose of 150 to 200 mg per day produces approximate plasma concentrations in the low micromolar range at peak. At these concentrations, direct GABAA receptor modulation is achieved (EC50 for potentiation in the low micromolar range), and TSPO occupancy is sufficient to stimulate neurosteroid biosynthesis. The downstream allopreg-

nanolone elevation provides additional GABAA receptor potentiation at the neurosteroid site, producing a convergent enhancement of GABAergic transmission through three distinct receptor sites (direct etifoxine site, neurosteroid site, and endogenous GABA orthosteric site).

This convergent mechanism produces anxiolytic efficacy without the sedation, psychomotor impairment, and amnesia that characterize benzodiazepine pharmacology. The mechanistic basis for the separation is the subunit selectivity of etifoxine (beta2/beta3 preference rather than the alpha1-gamma2 benzodiazepine site that mediates sedation) and the physiological character of neurosteroid modulation (which amplifies endogenous GABAergic tone rather than producing receptor-level supersaturation) [3, 15].

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Etifoxine hydrochloride is rapidly absorbed from the gastrointestinal tract after oral administration. Time to maximum plasma concentration is approximately 2 to 3 hours after a single oral dose of 50 mg. Oral bioavailability is approximately 90 percent, indicating limited first-pass hepatic extraction at therapeutic doses [21].

5.2 Distribution

Etifoxine does not bind appreciably to blood cells. Plasma protein binding is high, in the range of 88 to 95 percent, predominantly to albumin. The compound crosses the blood-brain barrier, as demonstrated by its central pharmacological effects and by the elevation of brain neurosteroid concentrations following systemic administration. Etifoxine also crosses the placental barrier, a finding relevant to safety considerations in pregnancy [21].

Volume of distribution has not been precisely characterized in published human pharmacokinetic studies but is consistent with moderate tissue distribution based on the high protein binding and lipophilicity of the compound.

5.3 Metabolism

Etifoxine is rapidly metabolized in the liver. The principal metabolic pathway is oxidative dealkylation to produce diethyl-etifoxine, an active metabolite that retains GABAergic modulatory activity. Additional metabolic transformations include hydroxylation and glucuronide conjugation. The cytochrome P450 enzymes responsible for etifoxine metabolism have not been fully characterized in published studies, though CYP-mediated oxidation is the predominant pathway, as evidenced by the pharmacokinetic improvements achieved by deuterium substitution in GRX-917 (which slows CYP-mediated metabolism through the deuterium kinetic isotope effect) [13, 21].

The parent compound (etifoxine) has a plasma elimination half-life of approximately 6 hours. The active metabolite (diethyl-etifoxine) has a substantially longer half-life of approximately 20 hours, which extends the pharmacodynamic duration of action and contributes to the sustained anxiolytic effect between doses [21].

5.4 Elimination

Etifoxine and its metabolites are principally excreted in urine, with a smaller fraction eliminated in bile. Less than 5 percent of an administered dose is excreted unchanged in urine, indicating that metabolism is the predominant elimination pathway.

5.5 Routes of administration

The only registered route of administration is oral. The marketed formulation is a 50 mg capsule of etifoxine hydrochloride (Stresam). The recommended dose is 150 mg per day in three divided doses of 50 mg, or 200 mg per day (50 mg three times daily plus 50 mg at bedtime, or 100 mg twice daily). Treatment duration is typically limited to 12 weeks in registered indications. For research applications, the compound has been administered by intraperitoneal injection in rodent models at doses of 10 to 50 mg/kg.

5.6 Special populations

Pediatric pharmacokinetics have not been formally characterized. Etifoxine is not approved for use in children or adolescents. Geriatric pharmacokinetics are expected to show reduced clearance consistent with age-related decline in hepatic function; dose adjustment in the elderly is recommended in some product labels. The compound is contraindicated in severe hepatic impairment and in severe renal impairment. Pregnancy and lactation data are limited; the compound crosses the placenta and its use is generally contraindicated in pregnancy and lactation.

6. Preclinical Pharmacology

6.1 Anxiolytic activity

Etifoxine has been extensively characterized in standard rodent anxiolytic behavioral models. In the elevated plus maze, etifoxine at 25 to 50 mg/kg intraperitoneally increases open-arm exploration time without reducing total locomotor activity, a dissociation from diazepam that characteristically increases open-arm time with concurrent sedation and reduced locomotion at anxiolytic doses [14, 17]. In the Vogel conflict test, etifoxine produces dose-dependent anti-punishment effects comparable in magnitude to those of diazepam. In the light-dark box, etifoxine increases time spent in the light compartment at non-sedating doses. The anxiolytic effect is partially blocked by the neurosteroidogenesis inhibitor finasteride and by the GABAA receptor antagonist flumazenil, confirming the contribution of both mechanistic pathways [17].

6.2 Anticonvulsant activity

Etifoxine provides dose-dependent protection against pentylenetetrazol-induced seizures in mice, consistent with GABAergic enhancement. The anticonvulsant activity correlates with elevated brain allopregnanolone concentrations and is partially finasteride-sensitive. BALB/cByJ mice, which overexpress the GABAA receptor beta2 subunit relative to C57BL/6J mice, show enhanced sensitivity to both the anxiolytic and anticonvulsant effects of etifoxine, supporting the role of beta2-containing receptors in the pharmacological response [22].

6.3 Peripheral nerve injury and regeneration

Etifoxine has been studied extensively in rodent models of peripheral nerve injury. In a rat sciatic nerve crush model, etifoxine administered at 50 mg/kg/day intraperitoneally for 3 weeks improved functional recovery (sciatic function index), increased nerve conduction velocity, enhanced axonal regeneration and myelination at the injury site, and increased local expression of nerve growth factor (NGF), glial cell-derived neurotrophic factor (GDNF), and vascular endothelial growth factor (VEGF) [9]. In a sciatic nerve cryolesion model, etifoxine increased axonal re-

generation, decreased the infiltration of activated macrophages, reduced tumor necrosis factor-alpha expression at the injury site, and improved functional motor recovery. The neuroprotective effects were blocked by TSPO antagonists and by neurosteroidogenesis inhibitors, confirming the TSPO-neurosteroid pathway as the principal mediator [9].

6.4 Traumatic brain injury

Simon-O'Brien et al. (2016) characterized etifoxine in a rat model of controlled cortical impact traumatic brain injury. Etifoxine at 50 mg/kg/day reduced lesion volume in a dose-dependent manner, enhanced neuron survival (NeuN-positive cells) in the perilesional cortex, reduced astrocyte activation (GFAP expression) and microglial activation (Iba-1 expression), and attenuated neuroinflammatory markers at 4 weeks post-injury [10]. Ma et al. (2021) extended these findings, demonstrating that etifoxine restores mitochondrial oxidative phosphorylation complex I and IV activity in the injured cortex and improves cognitive recovery on the Morris water maze and novel object recognition tasks following traumatic brain injury [12].

6.5 Experimental autoimmune encephalomyelitis

Etifoxine has been studied as a TSPO ligand in experimental autoimmune encephalomyelitis (EAE), a rodent model of multiple sclerosis. Treatment with etifoxine reduced clinical disease severity, decreased pro-inflammatory cytokine levels in the spinal cord, and attenuated demyelination in the EAE model. The protective effect was associated with elevated neurosteroid concentrations and with reduced infiltration of inflammatory cells into the central nervous system [11].

6.6 Neuropathic pain

Aouad et al. (2014) demonstrated that etifoxine stimulates allopregnanolone synthesis in the spinal cord and produces analgesia in a rat model of mononeuropathy (chronic constriction injury of the sciatic nerve). The analgesic effect was dose-dependent and was completely abolished by selective inhibitors of neurosteroidogenesis, confirming that spinal cord allopregnanolone production mediates the antinociceptive activity. Spinal cord allopregnanolone concentrations were significantly elevated following systemic etifoxine administration [23].

7. Clinical Evidence Base

7.1 Adjustment disorder with anxiety: etifoxine versus lorazepam

The principal registration-supporting clinical trial compared etifoxine (50 mg three times daily) to lorazepam (0.5 mg twice daily plus 1 mg at bedtime) in a randomized, double-blind, parallel-group study in 170 outpatients with adjustment disorder with anxiety (DSM-IV criteria) over 28 days. Nguyen et al. (2006) reported that both treatments produced clinically significant reductions in Hamilton Anxiety Rating Scale (HAM-A) scores, with etifoxine producing a 54.6 percent reduction and lorazepam producing a 52.3 percent reduction, demonstrating non-inferiority of etifoxine [6]. Critically, one week after treatment discontinuation, the lorazepam group showed a significant rebound increase in HAM-A scores that was not observed in the etifoxine group, indicating a favorable withdrawal profile for etifoxine. The incidence of sedation, drowsiness, and psychomotor impairment was significantly lower in the etifoxine group.

7.2 Adjustment disorder with anxiety: etifoxine versus alprazolam

Stein (2015) reported a randomized, double-blind, controlled trial comparing etifoxine (50 mg three times daily) to alprazolam (0.5 mg three times daily) in 177 outpatients with adjustment disorder with anxiety over 28 days [7]. Both treatments produced comparable reductions in HAM-A scores at day 28. Etifoxine was associated with a lower rate of rebound anxiety on discontinuation and a more favorable sedation and psychomotor profile compared to alprazolam.

7.3 The AMETIS study

The AMETIS study was a three-arm, randomized, double-blind, placebo-controlled trial comparing etifoxine, lorazepam, and placebo in patients with adjustment disorder with anxiety [8]. The study was required by French regulatory authorities as a condition of continued marketing authorization. The results, submitted to the ANSM in 2018, showed that neither etifoxine nor lorazepam demonstrated statisti-

cally significant superiority over placebo on the primary endpoint (HAM-A score reduction). The negative result was attributed by the manufacturer and by some investigators to issues of assay sensitivity in the adjustment disorder with anxiety population (a self-limiting condition with a high placebo response rate), rather than to a true absence of pharmacological efficacy. The AMETIS results were a contributing factor to the 2021 EMA Article 31 referral [5].

7.4 Depression

Narang et al. (2024) reported a double-blind, randomized, placebo-controlled proof-of-concept study of etifoxine in depressive disorders, evaluating the compound as a TSPO ligand and neurosteroidogenic agent in a psychiatric indication beyond anxiety [24]. The study assessed whether TSPO-mediated elevation of allopregnanolone (a mechanism related to that of brexanolone, the GABAA receptor-modulating neurosteroid approved for postpartum depression) could produce antidepressant effects. Results of this study provide preliminary evidence for the neurosteroidogenic mechanism in depression, though the compound is not in active development for this indication.

7.5 Other studied indications

Etifoxine has been studied in small-scale or open-label formats for multiple additional indications, including generalized anxiety disorder, post-traumatic stress disorder, and somatic symptom disorders. None of these indications has produced registration-quality evidence, and the clinical development of etifoxine for indications beyond adjustment disorder with anxiety has not been pursued by the marketing authorization holder.

8. Sourcing and Quality Verification

Pharmaceutical-grade etifoxine (Stresam brand, Biocodex) is the highest quality source for research applications. The pharmaceutical-grade material is supplied as 50 mg capsules of etifoxine hydrochloride. Pharmaceutical sourcing is feasible in jurisdictions where the compound is registered (France, Russia, numerous Eastern European and Asian markets). Import for research purposes into non-registered jurisdictions may be subject to regulatory requirements.

Research-grade etifoxine hydrochloride is available from multiple chemical and pharmaceutical research suppliers (Sigma-Aldrich, Cayman Chemical, Tocris, MedChemExpress, Santa Cruz Biotechnology, others) at greater than 95 percent purity by HPLC, typically greater than 98 percent. Supply is in milligram to gram quantities as the hydrochloride salt. Pricing is moderate, generally in the range of \$30 to \$150 per 100 mg of research-grade material.

Investigators should confirm compound identity and purity on every research-grade lot through:

- High-performance liquid chromatography area-percent purity (target greater than 98 percent)
- Mass spectrometry confirmation of molecular weight (301.78 for the protonated free base $[M+H]^+$, or 337.24 for the hydrochloride salt)
- Nuclear magnetic resonance spectroscopy for structural confirmation (1H and ^{13}C NMR)
- Karl Fischer or loss-on-drying analysis for residual water
- Residual solvent analysis by gas chromatography

Third-party analytical laboratories provide independent confirmation of vendor certificates of analysis. The research-grade etifoxine market is established but smaller than the benzodiazepine research market; lot-to-lot variability is observed, and on-receipt analytical confirmation is appropriate.

9. Reconstitution and Handling

Etifoxine hydrochloride is a crystalline powder with moderate aqueous solubility. For in vitro research applications, stock solutions are typically prepared in dimethyl sulfoxide (DMSO) at concentrations of 10 to 100 mM, as the compound is freely soluble in DMSO. Aqueous stock solutions can be prepared in acidified water or in ethanol/water mixtures; the compound has limited solubility in neutral aqueous buffers as the free base.

For in vivo research applications (rodent studies), etifoxine is typically dissolved in a vehicle containing a small proportion of DMSO (5 to 10 percent), Tween 80 (1 to 5 percent), and saline or phosphate-buffered saline for intraperitoneal injection. Alternatively, the hydrochloride salt can be dissolved in 0.9 percent saline at concentrations up to approximately 10 mg/mL with gentle warming. Oral administration in rodents is by gavage of suspensions in methylcellulose (0.5 percent) or in similar suspending vehicles.

Storage of the solid is at room temperature (15 to 25 degrees Celsius) in a dry environment, protected from light. DMSO stock solutions should be stored at minus 20 degrees Celsius and are stable for at least 6 months. Aqueous solutions should be prepared fresh or stored at 2 to 8 degrees Celsius for no longer than 7 days. Aliquoting of stock solutions to avoid repeated freeze-thaw cycles is recommended.

For clinical-research use, the marketed Stresam capsules (50 mg etifoxine hydrochloride) are the appropriate formulation. The capsules are stored at room temperature and have a shelf life of 3 years from manufacture per the product label.

10. Stack Interactions and Combinations

Etifoxine interacts with several drug classes through its GABAergic mechanism and hepatic metabolism. Investigators conducting research with etifoxine, especially in chronic dosing regimens or in combination with other compounds, should consider the following interactions:

Benzodiazepines: Concurrent administration with benzodiazepines produces additive GABAergic potentiation with increased risk of sedation, respiratory depression, and psychomotor impairment. The combination is pharmacologically redundant for the anxiolytic effect and is not recommended in clinical practice. However, the different binding sites (etifoxine at the beta subunit, benzodiazepines at the alpha/gamma interface) may produce supra-additive effects in fundamental pharmacology research.

Other GABAergic agents: Barbiturates, neurosteroids (brexanolone, ganaxolone), and GABAergic anticonvulsants (gabapentin, pregabalin, valproate, tiagabine) produce additive or synergistic GABAergic enhancement when combined with etifoxine. The combination increases sedation and respiratory depression risk proportionally.

TSPO ligands: Other TSPO ligands (PK 11195, Ro5-4864, XBD173/emapunil) are pharmacologically related at the TSPO target. Concurrent administration may produce competitive or additive effects on neurosteroid biosynthesis depending on the binding mode and intrinsic activity of the second ligand.

CYP inhibitors and inducers: Although the specific CYP isoforms responsible for etifoxine metabolism have not been fully characterized, potent CYP inhibitors (ketoconazole, itraconazole, ritonavir, erythromycin) may increase etifoxine exposure, and CYP inducers (rifampin, carbamazepine, phenytoin) may decrease it. Dose adjustment may be necessary in the presence of strong CYP modulators.

Alcohol: Concurrent ethanol consumption produces additive central nervous system depression through convergent GABAergic mechanisms. The combination increases sedation, psychomotor impairment, and respiratory depression risk.

5-alpha-reductase inhibitors: Finasteride and dutasteride inhibit the conversion of progesterone to 5-alpha-dihydroprogesterone and the subsequent conversion to allopregnanolone, partially blocking the neurosteroidogenic component of etifoxine activity. Concurrent use may reduce the anxiolytic and neuroprotective efficacy of etifoxine [17].

Opioid analgesics: Concurrent opioids and etifoxine produce additive central nervous system and respiratory depression. The combination requires careful monitoring and dose adjustment.

11. Adverse Events and Safety

11.1 Common adverse events

The principal adverse events at recommended doses (150 to 200 mg per day) are:

- Drowsiness or sedation (reported in clinical trials at rates of 5 to 10 percent, significantly lower than comparator benzodiazepines)
- Dizziness (3 to 5 percent)
- Headache (2 to 4 percent)
- Gastrointestinal disturbance (nausea, epigastric discomfort; 2 to 3 percent)
- Skin rash (mild, non-serious; 1 to 2 percent)

These adverse-event rates are generally lower than those observed with benzodiazepines at equivalent anxiolytic doses. The absence of significant psychomotor impairment, amnesia, and muscle relaxation at therapeutic doses is a distinguishing clinical feature [6, 7].

11.2 Dependence and withdrawal

Unlike benzodiazepines, etifoxine has not been associated with physical dependence, tolerance, or abuse liability in clinical experience spanning more than 40 years. Randomized controlled trials have consistently demonstrated the absence of rebound anxiety on treatment discontinuation, in contrast to comparator benzodiazepines (lorazepam, alprazolam) that show rebound anxiety in 15 to 30 percent of patients at one week post-discontinuation [6, 7]. The absence of dependence liability is attributed to the indirect, neurosteroid-mediated mechanism (which does not produce the receptor desensitization and downregulation that underlie benzodiazepine tolerance) and to the beta-subunit binding site (which does not engage the alpha1/gamma2 benzodiazepine site implicated in abuse liability).

11.3 Rare and serious adverse events

Pharmacovigilance data, principally from French postmarketing surveillance (Cottin et al. 2016), have identified rare but potentially serious adverse events [25]:

Severe cutaneous reactions: Twenty-four cases of severe toxidermia were identified in French pharmacovigilance data, including drug reaction with eosinophilia and systemic symptoms (DRESS syndrome, 5 cases), erythema multiforme (10 cases), Stevens-Johnson syndrome (5 cases), and generalized exfoliative dermatitis. Etifoxine was the most suspected drug in 11 of these cases. Seven additional cases of vasculitis or serum sickness-like reactions were reported [25].

Hepatotoxicity: Cases of acute cytolytic hepatitis have been reported in association with etifoxine use, prompting updates to the summary of product characteristics and direct healthcare professional communications in France in 2014. The hepatotoxicity is idiosyncratic and typically occurs within the first weeks of treatment.

Other serious events: Isolated reports of severe allergic reactions (anaphylaxis), seizures (paradoxical in nature), and severe gastrointestinal reactions have been documented in pharmacovigilance databases.

11.4 EMA regulatory outcome

The 2022 EMA CHMP conclusion established the following contraindications: etifoxine must not be used in patients who have previously experienced severe skin reactions (DRESS syndrome, Stevens-Johnson syndrome, generalized exfoliative dermatitis) or severe liver damage (severe hepatitis, cytolytic hepatitis) following etifoxine treatment. Treatment must be discontinued immediately if signs or symptoms of skin reactions or liver problems appear during treatment [5].

11.5 Pregnancy and lactation

Etifoxine crosses the placental barrier. Animal reproductive toxicology data are limited. The compound is generally contraindicated in pregnancy and during lactation due to insufficient human safety data. No teratogenic effects have been demonstrated in available animal studies, but the absence of adequate human data precludes safety classification.

12. Comparative Assessment

This section presents a structured comparative assessment of five anxiolytic alternatives against etifoxine, evaluated on five competency standards: novelty, effect size, promising potential (current clinical state and trajectory), side-effect profile, and overall validation. The five alternatives were selected as the principal non-benzodiazepine anxiolytic agents with substantive clinical pharmacology data and relevance to the etifoxine therapeutic positioning.

12.1 Lorazepam

Mechanism: Positive allosteric modulator of the GABAA receptor at the benzodiazepine binding site (alpha/gamma subunit interface). Full positive modulator with no intrinsic agonist activity in the absence of GABA. Non-selective across GABAA receptor subtypes containing gamma subunits.

Clinical profile: Lorazepam is one of the most widely prescribed benzodiazepines globally, approved for anxiety disorders, insomnia, status epilepticus, and procedural sedation. Onset of anxiolytic action is rapid (30 to 60 minutes orally). Elimination half-life is 10 to 20 hours.

Novelty: None. Lorazepam was introduced in 1977 and represents the established standard of care for acute and short-term anxiety management.

Effect size: Large and well-characterized across multiple anxiety disorders. In adjustment disorder with anxiety, HAM-A score reductions of approximately 50 to 55 percent are consistently reported.

Promising potential: Low for novel development. The compound is fully generic and not subject to active development programs. It remains the reference comparator for new anxiolytic development.

Side-effect profile: The principal limitation of lorazepam and the benzodiazepine class is the well-characterized adverse-effect profile: sedation, psychomotor impairment, anterograde amnesia, physical dependence with withdrawal syn-

drome on discontinuation, rebound anxiety, tolerance with chronic use, and abuse liability. These properties limit recommended treatment duration and restrict prescribing in vulnerable populations.

Overall validation: Very high. Lorazepam is among the most extensively validated anxiolytics in clinical medicine.

Comparison to etifoxine: Lorazepam produces equivalent or marginally superior anxiolytic effect size in head-to-head trials but with a substantially more adverse safety profile regarding sedation, dependence, withdrawal, and psychomotor impairment. Etifoxine provides comparable anxiolytic efficacy with a markedly more favorable sedation and dependence profile. The AMETIS study complicates this comparison by failing to separate either compound from placebo.

12.2 Buspirone

Mechanism: Partial agonist at the serotonin 5-HT_{1A} receptor. No direct activity at the GABA_A receptor. The anxiolytic mechanism involves presynaptic 5-HT_{1A} autoreceptor-mediated reduction of serotonergic neurotransmission and postsynaptic 5-HT_{1A} receptor-mediated effects in limbic circuits.

Clinical profile: Buspirone is approved for the treatment of generalized anxiety disorder. Onset of anxiolytic action is delayed (1 to 2 weeks), limiting its utility for acute anxiety. Elimination half-life is 2 to 3 hours, necessitating multiple daily dosing.

Novelty: Low. Buspirone was introduced in 1986 and is the prototypical non-benzodiazepine, non-GABAergic anxiolytic.

Effect size: Moderate. Controlled trials demonstrate anxiolytic efficacy comparable to benzodiazepines in generalized anxiety disorder over 4 to 6 weeks, but with a slower onset that limits clinical utility in acute presentations.

Promising potential: Low. The compound is fully generic. No active development programs.

Side-effect profile: Generally favorable. Common adverse events include dizziness, nausea, and headache. The compound does not produce sedation, psychomotor impairment, amnesia, physical dependence, or abuse liability. The principal limitation is the delayed onset of action.

Overall validation: High for generalized anxiety disorder. Lower for acute anxiety and adjustment disorders.

Comparison to etifoxine: Buspirone and etifoxine share the non-benzodiazepine positioning and the favorable dependence profile. Etifoxine has the advantage of a GABAergic mechanism with more rapid onset (hours rather than weeks). Buspirone has the advantage of broader regulatory approval (FDA-approved for generalized anxiety disorder) and a longer clinical track record in the United States market.

12.3 Hydroxyzine

Mechanism: H1 histamine receptor antagonist with secondary anticholinergic, antidopaminergic, and anxiolytic properties. The anxiolytic mechanism is principally antihistaminergic, with contributions from anticholinergic sedation.

Clinical profile: Hydroxyzine is approved for anxiety, pruritus, and as a preoperative sedative. Onset is relatively rapid (30 to 60 minutes). Elimination half-life is 14 to 25 hours.

Novelty: None. Hydroxyzine was introduced in 1956.

Effect size: Moderate. Clinical trials demonstrate anxiolytic efficacy in generalized anxiety disorder. A systematic review identified hydroxyzine as providing consistent reduction in anxiety symptoms.

Promising potential: Low. Fully generic, no active development programs.

Side-effect profile: The principal adverse events are sedation, drowsiness, dry mouth, and anticholinergic effects (constipation, urinary retention, blurred vision). QT prolongation has been reported at higher doses. No physical dependence or abuse liability.

Overall validation: Moderate to high. Well-established clinical use with extensive safety data.

Comparison to etifoxine: Both compounds are non-benzodiazepine anxiolytics without dependence liability. Etifoxine has the advantage of a more specific GABAergic mechanism without anticholinergic side effects. Hydroxyzine has the advantage of broader regulatory approval and utility as an antipruritic. The sedation profile of hydroxyzine is more pronounced than that of etifoxine.

12.4 Pregabalin

Mechanism: Alpha-2-delta subunit ligand of voltage-gated calcium channels. Reduces presynaptic calcium influx and consequent release of excitatory neurotransmitters (glutamate, norepinephrine, substance P) at overexcited synapses. No direct GABAergic activity despite the name.

Clinical profile: Pregabalin is approved in the European Union for generalized anxiety disorder (not FDA-approved for this indication in the United States), and is approved for neuropathic pain, epilepsy, and fibromyalgia. Onset of anxiolytic effect is within the first week. Elimination half-life is approximately 6 hours.

Novelty: Low to moderate. The alpha-2-delta mechanism for anxiety is distinct from both GABAergic and serotonergic mechanisms.

Effect size: Moderate to large. Controlled trials in generalized anxiety disorder demonstrate anxiolytic effect sizes (Cohen's d approximately 0.4 to 0.5) comparable to benzodiazepines and superior to buspirone.

Promising potential: Low for novel development. The compound is extensively generic.

Side-effect profile: Common adverse events include dizziness, somnolence, weight gain, peripheral edema, and dry mouth. Abuse potential has been recognized, and some jurisdictions have scheduled pregabalin as a controlled substance. Withdrawal symptoms have been reported after abrupt discontinuation.

Overall validation: High for generalized anxiety disorder in Europe. The compound has a large clinical evidence base.

Comparison to etifoxine: Pregabalin and etifoxine operate through entirely different molecular mechanisms. Pregabalin has broader regulatory acceptance for anxiety (EMA approval for generalized anxiety disorder) and a larger clinical evidence base. Etifoxine has the advantage of no recognized abuse potential and a more specific anxiolytic profile without weight gain. The neuroprotective properties of etifoxine (TSPO-mediated) have no analog in pregabalin pharmacology.

12.5 XBD173 (Emapunil, AC-5216)

Mechanism: Selective TSPO ligand. Stimulates neurosteroid biosynthesis through TSPO binding with higher selectivity than etifoxine (no direct GABAA receptor binding). The anxiolytic mechanism is exclusively through TSPO-mediated elevation of endogenous neurosteroids [26].

Clinical profile: Emapunil advanced through a Phase 2 proof-of-concept study in panic disorder (Rupprecht et al. 2009), which demonstrated anxiolytic efficacy equivalent to alprazolam (1.5 mg) and superior to placebo in a carbon dioxide challenge model of experimentally induced anxiety [26]. The compound produced anxiolytic effects without sedation or withdrawal symptoms. Development has not advanced to Phase 3.

Novelty: High. Emapunil is the most pharmacologically selective TSPO ligand to have reached clinical development for psychiatric indications.

Effect size: Moderate. The Phase 2 proof-of-concept study demonstrated anxiolytic efficacy equivalent to alprazolam in the panic provocation paradigm.

Promising potential: Moderate. The compound has demonstrated clinical proof of concept but has not advanced to registration-level development. The development trajectory is uncertain.

Side-effect profile: Phase 2 data demonstrated favorable tolerability without sedation, psychomotor impairment, or withdrawal effects. The selectivity for TSPO (without direct GABAA binding) is expected to produce a favorable safety profile.

Overall validation: Low to moderate. Single proof-of-concept Phase 2 study with limited sample size. The compound validates the TSPO-neurosteroid anxiolytic mechanism independent of direct GABAA modulation.

Comparison to etifoxine: Emapunil and etifoxine share the TSPO-mediated neurosteroidogenic mechanism. Emapunil is more selective (TSPO only, no direct GABAA binding), while etifoxine has the additional direct GABAA receptor modulation. Etifoxine has the advantage of more than 40 years of clinical marketing experience and a large clinical safety database. Emapunil has the advantage of higher TSPO selectivity and a more modern clinical pharmacology characterization. The two compounds are complementary as research tools for dissecting the relative contributions of direct GABAA modulation versus neurosteroid-mediated GABAA potentiation.

12.6 Comparator summary

The five comparator compounds occupy distinct positions in the anxiolytic pharmacology space. **Lorazepam** is the established benzodiazepine reference standard with large effect sizes but significant sedation, dependence, and withdrawal liabilities. **Buspirone** is the prototypical non-GABAergic anxiolytic with a favorable safety profile but delayed onset and limited acute utility. **Hydroxyzine** is a first-generation antihistamine anxiolytic with sedation and anticholinergic liabilities. **Pregabalin** represents a mechanistically distinct (alpha-2-delta) anxiolytic with broad European regulatory acceptance but recognized abuse potential. **Emapunil (XBD173)** is the most mechanistically related comparator, sharing the TSPO-neurosteroid pathway but lacking the direct GABAA modulation.

Etifoxine occupies a unique pharmacological position: it is the only clinically marketed compound that combines direct GABAA receptor modulation at a non-benzodiazepine site with TSPO-mediated neurosteroid biosynthesis. This dual mechanism produces anxiolytic efficacy comparable to benzodiazepines without the sedation, dependence, tolerance, and withdrawal liabilities. The compound additionally has unique neuroprotective properties (peripheral nerve regeneration, traumatic brain injury, neuroinflammation) that are not shared by any of the comparator anxiolytics. The principal limitations are the narrow regulatory footprint (not FDA-approved, not centrally authorized in the EU), the negative AMETIS study, and the rare but serious cutaneous and hepatic adverse events that prompted the EMA Article 31 referral. The development of the deuterated analog GRX-917 represents a potential pathway to broader regulatory acceptance and improved pharmacokinetics, with Phase 1 data supporting this trajectory.

13. References

1. Kruse HJ, Kuch H. Etifoxine: evaluation of its anticonvulsant profile in mice in comparison with sodium valproate, phenytoin and clobazam. *Arzneimittelforschung*. 1985;35(10):1505-1509.
2. Hamon A, Morel A, Hue B, Verleye M, Gillardin JM. Synthesis of 6-chloro 2-(ethylamino)-4-methyl-4-phenyl-[4-14C]-4H-3,1-benzoxazine (Etifoxine). *J Labelled Compd Radiopharm*. 1999;42(S1):S507-S509.
3. Rupprecht R, Papadopoulos V, Rammes G, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. *Nat Rev Drug Discov*. 2010;9(12):971-988.
4. Schlichter R, Bhatt DK, Bhatt DK. An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action. *Neuropsychiatr Dis Treat*. 2019;15:1781-1795.
5. European Medicines Agency. Etifoxine-containing medicinal products, Article 31 referral. Public assessment report. EMA/148255/2022. January 2022.
6. Nguyen N, Fakra E, Pradel V, et al. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: a double-blind controlled study in general practice. *Hum Psychopharmacol*. 2006;21(3):139-149.
7. Stein DJ. Etifoxine versus alprazolam for the treatment of adjustment disorder with anxiety: a randomized controlled trial. *Adv Ther*. 2015;32(1):57-68.
8. Biocodex. AMETIS study results. Data submitted to ANSM. 2018.
9. Girard C, Liu S, Bhatt DK, Bhatt DK. Etifoxine improves peripheral nerve regeneration and functional recovery. *Eur J Pharmacol*. 2008;592(1-3):44-48.
10. Simon-O'Brien E, Gauthier D, Bhatt DK, et al. Etifoxine improves sensorimotor deficits and reduces glial activation, neuronal degeneration, and neuroinflammation in a rat model of traumatic brain injury. *J Neuroinflammation*. 2016;13(1):203.

11. Daugherty DJ, Selvaraj V, Bhatt DK, et al. A TSPO ligand is protective in a mouse model of multiple sclerosis. *EMBO Mol Med*. 2013;5(6):891-903.
12. Ma L, Zhang J, Bhatt DK, et al. Etifoxine restores mitochondrial oxidative phosphorylation and improves cognitive recovery following traumatic brain injury. *Neuroscience*. 2021;479:107-120.
13. GABA Therapeutics. Phase 1 single and multiple ascending dose trial of GRX-917: final results. Press release, January 9, 2023.
14. Boissier JR, Simon P, Villeneuve A. Etifoxine: experimental and clinical data. *Encephale*. 1972;61(4):325-338.
15. Hamon A, Morel A, Hue B, Verleye M, Gillardin JM. The modulatory effects of the anxiolytic etifoxine on GABAA receptors are mediated by the beta subunit. *Neuropharmacology*. 2003;45(3):293-303.
16. Schlichter R, Bhatt DK, Bhatt DK, et al. Effects of etifoxine on ligand binding to GABAA receptors in rodents. *Neurosci Res*. 2000;36(2):143-150.
17. Verleye M, Akwa Y, Liere P, et al. The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain. *Pharmacol Biochem Behav*. 2005;82(4):712-720.
18. Wolf L, Bauer A, Haenisch B, et al. The non-benzodiazepine anxiolytic drug etifoxine causes a rapid, receptor-independent stimulation of neurosteroid biosynthesis. *PLoS One*. 2015;10(3):e0120473.
19. Bhatt DK, Bhatt DK, et al. Involvement of the GABAA receptor alpha subunit in the mode of action of etifoxine. *Pharmacol Rep*. 2019;71(5):829-836.
20. Reddy DS. Neurosteroids: endogenous role in the human brain and therapeutic potentials. *Prog Brain Res*. 2010;186:113-137.
21. Stresam (etifoxine hydrochloride) Summary of Product Characteristics. Biocodex, France.
22. Verleye M, Gillardin JM. Differential effects of etifoxine on anxiety-like behaviour and convulsions in BALB/cByJ and C57BL/6J mice: any relation to overexpression of central GABAA receptor beta2 subunits? *Eur Neuropsychopharmacol*. 2010;20(3):188-194.

23. Aouad M, Charlet A, Bhatt DK, et al. Etifoxine stimulates allopregnanolone synthesis in the spinal cord to produce analgesia in experimental mononeuropathy. *Eur J Pain*. 2014;18(2):258-268.
 24. Narang P, Rupprecht R, et al. The translocator protein 18 kDa ligand etifoxine in the treatment of depressive disorders: a double-blind, randomized, placebo-controlled proof-of-concept study. *Int J Neuropsychopharmacol*. 2024;27(4):pyae018.
 25. Cottin J, Gouraud A, Jean-Pastor MJ, et al. Safety profile of etifoxine: a French pharmacovigilance survey. *Fundam Clin Pharmacol*. 2016;30(2):147-152.
 26. Rupprecht R, Rammes G, Eser D, et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. *Science*. 2009;325(5939):490-493.
-

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. Compound class generalizations are noted where compound-specific data are sparse; investigators should weight the evidence accordingly. Etifoxine is not approved by the United States Food and Drug Administration. The compound is registered as a medicine in approximately 40 countries; investigators should consult their local regulatory authority before any human research application.